What is the Optimal Dose and Fractionation Schedule for Inoperable Node-Negative Large (≥ 5 cm) Non-Small Cell Lung Cancer?

Introduction: The optimal radiotherapy strategy for inoperable node-negative non-small cell lung cancer (NSCLC) ≥5 cm remains undefined. This study compared clinical outcomes of stereotactic body radiation therapy (SBRT), hypofractionated radiation therapy (HFRT), and conventionally fractionated radiation therapy (CRT) in this population.

Methods: This retrospective study included 137 patients with node-negative NSCLC ≥5 cm treated with SBRT (n = 37), HFRT (n = 56), or CRT (n = 44) from 2011 to 2023.

Refining Patient Selection for Prophylactic Cranial Irradiation in Limited-Stage SCLC: A Multicenter Cohort Study.

Background: We aimed to evaluate the efficacy of prophylactic cranial irradiation (PCI) in the contemporary management of limited-stage small cell lung cancer (LS-SCLC) and to identify optimal strategies for patient selection.

Patients And Methods: This multi-institutional cohort study included patients with LS-SCLC who underwent definitive chemoradiation between 2006 and 2022, all staged using brain MRI and PET. We compared the incidence of brain metastases (BM) and overall survival (OS) between patients who received PCI and those who did not.

Clinical effect of pulmonary rehabilitation during radiotherapy in lung cancer: A randomized controlled trial.

Objectives: Radiotherapy for lung cancer can cause lung injury, which may lead to decreased pulmonary function, worsened clinical symptoms, reduced quality of life, and poor prognosis. Given that patients with compromised lung function are more likely to undergo radiotherapy, adjunct treatments to enhance its safety should be explored. We performed this study to determine whether outpatient-based pulmonary rehabilitation (PR) provides positive clinical effects for patients with lung cancer undergoing radiotherapy.

Regular aerobic exercise ameliorates radiation-induced pulmonary fibrosis: An animal study.

Background And Purpose: A definitive treatment for radiation-induced pulmonary fibrosis (RIPF), a common side effect of radiation therapy for thoracic cancer, remains to be established. Pulmonary rehabilitation programs, including regular aerobic exercise, may ameliorate RIPF. However, a scientific basis supporting the protective effect of exercise against RIPF is lacking.

Deintensification of radiation dose to 20 Gy for conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma.

This study evaluated the efficacy and safety of 20.0 Gy versus 30.6 Gy radiotherapy for conjunctival MALT lymphoma in 76 lesions treated between 2010 and 2022.

Intraoperative radiotherapy IORT applicators for treatment of small skin lesions a phantom and planning study.

Radiation therapy is actively utilized for superficial lesions. External beam radiotherapy for cutaneous lesions utilizes electrons with low transmittance. Conventional electron beam therapy uses Cerrobend blocks for field shaping; however, the Intraoperative Radiotherapy (IORT) applicator offers superior dosimetric characteristics.

Stereotactic ablative radiotherapy for pulmonary metastasis from sarcoma: a retrospective comparison with metastasectomy.

Recent studies report excellent local control (LC) and favorable toxicities of stereotactic ablative radiotherapy (SABR) for pulmonary metastasis (PM) from sarcoma. This study compared the LC and survival of SABR and metastasectomy for sarcoma PM. We analyzed the LC rates of 54 PMs treated with SABR between 2008 and 2022.

Comparison of Metastasectomy and Stereotactic Body Radiation Therapy for Pulmonary Oligometastasis From Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.

Purpose: Although there is a growing role for local therapy in patients with hepatocellular carcinoma (HCC) and pulmonary oligometastasis, it remains unclear whether metastatectomy or stereotactic body radiation therapy (SBRT) is the more effective treatment for these patients. We aimed to compare the oncologic outcomes of metastasectomy and SBRT for HCC with pulmonary oligometastasis.

Methods And Materials: We retrospectively analyzed 209 patients with HCC with 322 metastatic lung lesions who underwent either metastasectomy (150 patients with 241 lesions) or SBRT (59 patients with 81 lesions) between January 2008 and December 2018.

Ibulocydine Inhibits Migration and Invasion of TNBC Cells via MMP-9 Regulation.

Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast cancer types, indicating a poor survival prognosis with a more aggressive biology of metastasis to the lung and a short response duration to available therapies. Ibulocydine (IB) is a novel (cyclin-dependent kinase) CDK7/9 inhibitor prodrug displaying potent anti-cancer effects against various cancer cell types. We performed in vitro and in vivo experiments to determine whether IB inhibits metastasis and eventually overcomes the poor drug response in TNBC.

Predictive value of primary tumor volume change during concurrent chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.

Background And Purpose: No established early biomarkers currently exist to predict responses during concurrent chemoradiotherapy (CCRT) in patients with unresectable non-small cell lung cancer (NSCLC). This study investigated the potential of gross tumor volume (GTV) and its changes during CCRT as predictors of survival outcomes.

Materials And Methods: We identified 227 patients with unresectable stage III NSCLC who underwent definitive CCRT followed by durvalumab between November 2018 and December 2022.

Diagnostic performance of a deep-learning model using F-FDG PET/CT for evaluating recurrence after radiation therapy in patients with lung cancer.

Objective: We developed a deep learning model for distinguishing radiation therapy (RT)-related changes and tumour recurrence in patients with lung cancer who underwent RT, and evaluated its performance.

Methods: We retrospectively recruited 308 patients with lung cancer with RT-related changes observed on F-fluorodeoxyglucose positron emission tomography-computed tomography (F-FDG PET/CT) performed after RT. Patients were labelled as positive or negative for tumour recurrence through histologic diagnosis or clinical follow-up after F-FDG PET/CT.

Safety and Efficacy of HL301 In Radiation Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer Receiving Curative Concurrent Chemoradiotherapy: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2a Clinical Trial.

Purpose: We aimed to investigate the safety and efficacy of HL301, a standardized combination product of 7 medicinal plants, in radiation pneumonitis in patients with unresectable non-small cell lung cancer undergoing curative concurrent chemoradiotherapy.

Methods And Materials: The target accrual was 87 and a total of 63 patients were enrolled due to poor accrual rate. We randomly assigned the 63 patients to receive a placebo (arm A), or 1200 mg HL301 (arm B), or 1800 mg HL301 (arm C).

Targeting phosphomevalonate kinase enhances radiosensitivity via ubiquitination of the replication protein A1 in lung cancer cells.

Radiotherapy (RT) plays an important role in localized lung cancer treatments. Although RT locally targets and controls malignant lesions, RT resistance prevents RT from being an effective treatment for lung cancer. In this study, we identified phosphomevalonate kinase (PMVK) as a novel radiosensitizing target and explored its underlying mechanism.

Deep learning proton beam range estimation model for quality assurance based on two-dimensional scintillated light distributions in simulations.

Background: Many studies have utilized optical camera systems with volumetric scintillators for quality assurances (QA) to estimate the proton beam range. However, previous analytically driven range estimation methods have the difficulty to derive the dose distributions from the scintillation images with quenching and optical effects.

Purpose: In this study, a deep learning method utilized to QA was used to predict the beam range and spread-out Bragg peak (SOBP) for two-dimensional (2D) map conversion from the scintillation light distribution (LD) into the dose distribution in a water phantom.

Challenges and Opportunities With the Use of Hypofractionated Radiation Therapy in Cancer Care: Regional Perspectives From South Korea, Japan, Singapore, and Australia.

Hypofractionated radiotherapy schedules provide higher per-fraction radiation doses delivered in fewer fractions than conventional schedules. This novel delivery method is supported by a large body of clinical trial evidence across various cancer sites in both curative and palliative settings. Hypofractionation is associated with benefits such as lower costs, improved patient access and increased treatment precision, which has led to its inclusion in various treatment guidelines.

Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR.

Introduction: This study aimed to investigate real-world evidence for efficacy and safety of durvalumab consolidation (DC) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC.

Methods: Patients with stage III NSCLC who started DC after CRT between September 2018 and December 2020 and were treated at five tertiary hospitals in the Republic of Korea were included. The primary end point was real-world progression-free survival (rwPFS).